Barely Significant
← all excerpts

Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis.

Blood Adv · 2025 · PMC12719173 · PMID 40795230

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantP < .001actually significant
The effects differed by study design: highly significant results favoring continued treatment were observed in case-control studies (OR, 0.04; 95% CI, 0.02-0.08; P < .001), whereas no statistically significant effects were seen in cohort studies (OR, 0.40; 95% CI, 0.15-1.09; P = .07).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.